A Food and Drug Administration report “very correctly identifies” a number of areas where the FDA could improve its combination product review process, an attorney told Bloomberg BNA Oct. 16.
Bradley Merrill Thompson, a Washington-based attorney with Epstein Becker & Green, P.C., said while he’s pleased the FDA released the report, “there are other steps the agency could take to strengthen combination product review.”
The FDA issued its report Oct. 14 on the combination product review process. The report includes several recommendations from an agency study team.
Combination products are made up of combinations of a drug, device and/or biological ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.